Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11398
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMackay, A J-
dc.contributor.authorAngus, Peter W-
dc.contributor.authorGow, Paul J-
dc.date.accessioned2015-05-16T00:59:20Z
dc.date.available2015-05-16T00:59:20Z
dc.date.issued2011-12-01-
dc.identifier.citationTransplantation Proceedings; 43(10): 3802-6en_US
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/11398en
dc.description.abstractIt has become common practice to withdraw or reduce calcineurin inhibitors (CNI) in patients with renal dysfunction after liver transplantation; however, little is known about the long-term outcome of this strategy. This study investigates the long-term results of CNI withdrawal for post-liver transplant renal dysfunction and examines for factors that predict a significant improvement in renal function.A retrospective database review was performed to examine outcomes in patients with CNI withdrawn for chronic renal impairment. Univariate analyses were used to identify predictors of an improvement in creatinine clearance (CrC).Sixty patients (44 males) were included. Of these, 82% of patients were switched to mycophenolate mofetil and 18% azathioprine. Median follow-up after CNI withdrawal was 48 (range 3-72) months. Postwithdrawal, there was an initial improvement in CrCl (mean 5.5 mL), which remained above baseline levels at 6 years. Acute cellular rejection developed in six patients (10%), but there was no rejection-associated graft loss. A shorter time from transplantation to conversion was associated with greatest improvement in CrCI.CNI withdrawal is associated with a significant initial improvement and then arrest in long-term decline of renal function. Rejection in this setting is uncommon. The greatest benefit is seen in patients switched within the early years after transplantation.en_US
dc.language.isoenen
dc.subject.otherAgeden
dc.subject.otherBiological Markers.metabolismen
dc.subject.otherCalcineurin Inhibitorsen
dc.subject.otherChronic Diseaseen
dc.subject.otherCreatinine.metabolismen
dc.subject.otherDrug Substitutionen
dc.subject.otherFemaleen
dc.subject.otherGraft Rejection.immunology.prevention & controlen
dc.subject.otherHumansen
dc.subject.otherImmunosuppressive Agents.adverse effectsen
dc.subject.otherKidney.drug effects.metabolism.physiopathologyen
dc.subject.otherKidney Diseases.diagnosis.etiology.metabolism.physiopathologyen
dc.subject.otherLiver Transplantation.adverse effects.immunologyen
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherRisk Assessmenten
dc.subject.otherRisk Factorsen
dc.subject.otherTime Factorsen
dc.subject.otherTreatment Outcomeen
dc.subject.otherVictoriaen
dc.titleLong-term outcomes of calcineurin inhibitor withdrawal for post-liver transplant renal dysfunction.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleTransplantation Proceedingsen_US
dc.identifier.affiliationVictorian Liver Transplant Uniten_US
dc.identifier.doi10.1016/j.transproceed.2011.10.044en_US
dc.description.pages3802-6en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/22172850en
dc.type.contentTexten_US
dc.type.austinJournal Articleen
local.name.researcherAngus, Peter W
item.grantfulltextnone-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
crisitem.author.deptVictorian Liver Transplant Unit-
crisitem.author.deptGastroenterology and Hepatology-
crisitem.author.deptVictorian Liver Transplant Unit-
crisitem.author.deptGastroenterology and Hepatology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

20
checked on Sep 9, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.